Biomarker-driven diagnosis of diffuse gliomas

Molecular Aspects of Medicine

Volumn 45, Issue , 2015, Pages 87-96

  Appin, Christina L ^a   Brat, Daniel J ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

1p 19q; Astrocytoma; ATRX; Biomarker; BRAF; EGFR; Glioblastoma; Glioma; H3F3A; IDH; Oligodendroglioma; TERT; TP53

Indexed keywords

ISOCITRATE DEHYDROGENASE; TUMOR MARKER; B RAF KINASE; BRAF PROTEIN, HUMAN; CIC PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA HELICASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FUBP1 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, HUMAN; REPRESSOR PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; ASTROCYTOMA; ATRX GENE; CANCER GRADING; CDKN2A GENE; CDKN2B GENE; CHROMOSOME 19Q; CHROMOSOME 1P; CIC GENE; CYTOGENETICS; DAXX GENE; EGFR GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUBP1 GENE; GENE DELETION; GLIOBLASTOMA; GLIOMA; H3F3A GENE; HISTOPATHOLOGY; HUMAN; IDH GENE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NF1 GENE; NOTCH1 GENE; OLIGODENDROGLIOMA; PDGFRA GENE; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; PREDICTION; PROGNOSIS; PROMOTER REGION; PTEN GENE; TERT GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; CHROMOSOME 1; CHROMOSOME DELETION; GENE REARRANGEMENT; GENETICS; METABOLISM;

BIOMARKERS, TUMOR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DNA HELICASES; DNA-BINDING PROTEINS; GENE REARRANGEMENT; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; REPRESSOR PROTEINS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84946492585     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2015.05.002     Document Type: Review

References (87)

1. K. Aldape, P.C. Burger, and A. Perry Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma Arch. Pathol. Lab. Med 131 2 2007 242 251
2. C.L. Appin, and D.J. Brat Molecular genetics of gliomas Cancer J. 20 1 2014 66 72
3. C.L. Appin, Gao J., C. Chisolm, and et al. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics Brain Pathol 23 4 2013 454 461
4. P. Bailey, and H. Cushing A Classification of the Tumors of the Glioma Group on a Histogenic Basis with a Correlated Study of Prognosis 1926 JB Lippincott Co Philadelphia, PA
5. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 6 2008 597 602
6. C. Bettegowda, N. Agrawal, Jiao Y., and et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma Science 333 6048 2011 1453 1455
7. S.H. Bigner, B.K. Rasheed, R. Wiltshire, and R.E. McLendon Morphologic and molecular genetic aspects of oligodendroglial neoplasms Neuro-Oncol 1 1 1999 52 60
8. T.D. Bourne, and D. Schiff Update on molecular findings, management and outcome in low-grade gliomas Nat. Rev. Neurol 6 12 2010 695 701
9. D.J. Brat, R.A. Prayson, T.C. Ryken, and J.J. Olson Diagnosis of malignant glioma: role of neuropathology J. Neurooncol 89 3 2008 287 311
10. D.J. Brat, P.T. Cagle, D.A. Dillon, and et al. Template for reporting results of biomarker testing of specimens from patients with tumors of the central nervous system Arch. Pathol. Lab. Med 2015 10.5858/arpa.2014-0588-CP
11. M. Brell, A. Tortosa, E. Verger, and et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas Clin. Cancer Res 11 14 2005 5167 5174
12. C.W. Brennan, R.G. Verhaak, A. McKenna, and et al. The somatic genomic landscape of glioblastoma Cell 155 2 2013 462 477
13. D.K. Broderick, Di C., T.J. Parrett, and et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas Cancer Res 64 15 2004 5048 5050
14. A. Burford, S.E. Little, A. Jury, and et al. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma PLoS ONE 8 8 2013 e71777
15. D. Capper, S. Weissert, J. Balss, and et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 1 2010 245 254
16. K.M. Chan, Fang D., Gan H., and et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression Genes Dev 27 9 2013 985 990
17. S.W. Coons, P.C. Johnson, B.W. Scheithauer, A.J. Yates, and D.K. Pearl Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas Cancer 79 7 1997 1381 1393
18. J.B. Cryan, S. Haidar, L.A. Ramkissoon, and et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas Oncotarget 5 18 2014 8083 8092
19. Dang L., D.W. White, S. Gross, and et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 7274 2009 739 744
20. D. Dias-Santagata, Q. Lam, K. Vernovsky, and et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications PLoS ONE 6 3 2011 e17948
21. M.J. Dougherty, M. Santi, M.S. Brose, and et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas Neuro-Oncol 12 7 2010 621 630
22. J.E. Eckel-Passow, D.H. Lachance, A.M. Molinaro, and et al. Glioma groups based on TERT promoter mutation, IDH mutation, and 1p/19q codeletion N. Engl. J. Med 2015 (in press)
23. M. Esteller, S.R. Hamilton, P.C. Burger, S.B. Baylin, and J.G. Herman Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 4 1999 793 797
24. M. Esteller, J. Garcia-Foncillas, E. Andion, and et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N. Engl. J. Med 343 19 2000 1350 1354
25. A. Gajjar, S.M. Pfister, M.D. Taylor, and R.J. Gilbertson Molecular insights into pediatric brain tumors have the potential to transform therapy Clin. Cancer Res 20 22 2014 5630 5640
26. C. Giannini, B.W. Scheithauer, A.L. Weaver, and et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading J. Neuropathol. Exp. Neurol 60 3 2001 248 262
27. C. Hartmann, J. Meyer, J. Balss, and et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 4 2009 469 474
28. M.E. Hegi, A.C. Diserens, T. Gorlia, and et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med 352 10 2005 997 1003
29. M.E. Hegi, R.C. Janzer, W.L. Lambiv, and et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial Acta Neuropathol 123 6 2012 841 852
30. R.B. Jenkins, H. Blair, K.V. Ballman, and et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 20 2006 9852 9861
31. Jiao Y., P.J. Killela, Z.J. Reitman, and et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Oncotarget 3 7 2012 709 722
32. D.T. Jones, S. Kocialkowski, Liu L., and et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas Cancer Res 68 21 2008 8673 8677
33. P.J. Killela, Z.J. Reitman, Jiao Y., and et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal PNAS 110 15 2013 6021 6026
34. C. Komine, T. Watanabe, Y. Katayama, A. Yoshino, T. Yokoyama, and T. Fukushima Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas Brain Pathol 13 2 2003 176 184
35. A. Korshunov, J. Meyer, D. Capper, and et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 3 2009 401 405
36. R.C. Laxton, S. Popov, L. Doey, and et al. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma Neuro-Oncol 15 12 2013 1635 1643
37. D. Lee, Y.L. Suh, Kang S.Y., T.I. Park, J.Y. Jeong, and S.H. Kim IDH1 mutations in oligodendroglial tumors: comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR Brain Pathol 23 3 2013 285 293
38. P.W. Lewis, M.M. Muller, M.S. Koletsky, and et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma Science 340 6134 2013 857 861
39. Liu X.Y., N. Gerges, A. Korshunov, and et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations Acta Neuropathol 124 5 2012 615 625
40. D.N. Louis, H. Ohgaki, O.D. Wiestler, and W.K. Cavenee WHO Classification of Tumours of the Central Nervous System fourth ed. 2007 Intl. Agency for Research Lyon
41. D.N. Louis, A. Perry, P. Burger, and et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading Brain Pathol 24 5 2014 429 435
42. D. Loussouarn, A.G. Le Loupp, J.S. Frenel, and et al. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas Int. J. Oncol 40 6 2012 2058 2062
43. Lu C., P.S. Ward, G.S. Kapoor, and et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 7390 2012 474 478
44. J.A. Maxwell, S.P. Johnson, J.A. Quinn, and et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma Mol. Cancer Ther 5 10 2006 2531 2539
45. M. Mellai, A. Piazzi, V. Caldera, and et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors J. Neurooncol 105 2 2011 345 357
46. M. Mellai, O. Monzeglio, A. Piazzi, and et al. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors J. Neurooncol 107 3 2012 617 631
47. P. Metellus, B. Coulibaly, C. Colin, and et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Acta Neuropathol 120 6 2010 719 729
48. M. Nakamura, T. Watanabe, Y. Yonekawa, P. Kleihues, and H. Ohgaki Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene Carcinogenesis 22 10 2001 1715 1719
49. H. Noushmehr, D.J. Weisenberger, K. Diefes, and et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 5 2010 510 522
50. H. Ohgaki, and P. Kleihues Genetic profile of astrocytic and oligodendroglial gliomas Brain Tumor Pathol 28 3 2011 177 183
51. H. Ohgaki, and P. Kleihues The definition of primary and secondary glioblastoma Clin. Cancer Res 19 4 2013 764 772
52. Y. Okamoto, P.L. Di Patre, C. Burkhard, and et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas Acta Neuropathol 108 1 2004 49 56
53. A. Olar, K.M. Wani, K.D. Alfaro-Munoz, and et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas Acta Neuropathol 129 4 2015 585 596
54. Q.T. Ostrom, H. Gittleman, P. Farah, and et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neuro-Oncol 15 Suppl. 2 2013 ii1 ii56
55. D.W. Parsons, S. Jones, Zhang X., and et al. An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 2008 1807 1812
56. A. Perry, and D.J. Brat Practical Surgical Neuropathology: A Diagnostic Approach 2010 Churchill Livingstone Philadelphia, PA
57. J.J. Phillips, D. Aranda, D.W. Ellison, and et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma Brain Pathol 23 5 2013 565 573
58. I.F. Pollack, R.L. Hamilton, R.W. Sobol, and et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group Childs Nerv. Syst 27 1 2011 87 94
59. M. Preusser, R. Charles Janzer, J. Felsberg, and et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 4 2008 520 532
60. D.E. Reuss, F. Sahm, D. Schrimpf, and et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma Acta Neuropathol 129 1 2015 133 146
61. G. Reyes-Botero, C. Dehais, A. Idbaih, and et al. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression Neuro-Oncol 16 5 2014 662 670
62. F.J. Rodriguez, S.N. Thibodeau, R.B. Jenkins, and et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma Appl. Immunohistochem. Mol. Morphol 16 1 2008 59 65
63. F.J. Rodriguez, K.S. Lim, D. Bowers, and C.G. Eberhart Pathological and molecular advances in pediatric low-grade astrocytoma Annu. Rev. Pathol 8 2013 361 379
64. F.J. Rodriguez, T. Tihan, Lin D., and et al. Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients Am. J. Surg. Pathol 38 8 2014 1058 1070
65. F. Sahm, C. Koelsche, J. Meyer, and et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas Acta Neuropathol 123 6 2012 853 860
66. F. Sahm, D. Reuss, C. Koelsche, and et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma Acta Neuropathol 128 4 2014 551 559
67. G. Schindler, D. Capper, J. Meyer, and et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Acta Neuropathol 121 3 2011 397 405
68. J. Schwartzentruber, A. Korshunov, Liu X.Y., and et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 482 7384 2012 226 231
69. R. Stupp, W.P. Mason, M.J. van den Bent, and et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med 352 10 2005 987 996
70. D. Sturm, H. Witt, V. Hovestadt, and et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma Cancer Cell 22 4 2012 425 437
71. D. Sturm, S. Bender, D.T. Jones, and et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge Nat. Rev. Cancer 14 2 2014 92 107
72. S. Takano, Tian W., M. Matsuda, and et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing Brain Tumor Pathol 28 2 2011 115 123
73. The Cancer Genome Atlas Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 7216 2008 1061 1068
74. The Cancer Genome Atlas Research Network Comprehensive, integrative genomic analysis of diffuse lower grade gliomas N. Engl. J. Med 2015 (in press)
75. B.J. Theeler, W.K. Yung, G.N. Fuller, and J.F. De Groot Moving toward molecular classification of diffuse gliomas in adults Neurology 79 18 2012 1917 1926
76. M. Toyota, N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin, and J.P. Issa CpG island methylator phenotype in colorectal cancer Proc. Natl. Acad. Sci. U.S.A. 96 15 1999 8681 8686
77. D.J. van Meyel, D.A. Ramsay, A.G. Casson, M. Keeney, A.F. Chambers, and J.G. Cairncross p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression J. Natl Cancer Inst 86 13 1994 1011 1017
78. R.G. Verhaak, K.A. Hoadley, E. Purdom, and et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 1 2010 98 110
79. H. Wakimoto, S. Tanaka, W.T. Curry, and et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas Clin. Cancer Res 20 11 2014 2898 2909
80. K. Watanabe, K. Sato, W. Biernat, and et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies Clin. Cancer Res 3 4 1997 523 530
81. T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am. J. Pathol 174 4 2009 1149 1153
82. B. Wiestler, D. Capper, M. Sill, and et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma Acta Neuropathol 128 4 2014 561 571
83. Xu W., Yang H., Liu Y., and et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 19 1 2011 17 30
84. Xu X., Zhao J., Xu Z., and et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity J. Biol. Chem 279 32 2004 33946 33957
85. Yan H., D.W. Parsons, Jin G., and et al. IDH1 and IDH2 mutations in gliomas N. Engl. J. Med 360 8 2009 765 773
86. S. Yip, Y.S. Butterfield, O. Morozova, and et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers J. Pathol 226 1 2012 7 16
87. Zhang J., Wu G., C.P. Miller, and et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas Nat. Genet 45 6 2013 602 612